HBV Reactivation Rituximab — RACP Adult Medicine MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — HBV reactivation – continue antiviral throughout + 12–18 months after rituximab cessation
Rituximab: very high HBV reactivation risk (50–80% without prophylaxis). Continue antiviral throughout + ≥12–18 months post last rituximab. Monitor HBV DNA.
Reference: eTG – 2025; AASLD – 2018